Recent policy changes help increase access to recommended non-invasive colorectal cancer screening tests. These policy changes require Medicare and most commercial insurers to pay for colonoscopy after a positive Cologuard test without cost to the patient. For most patients, these financial protections take effect starting Jan. 1.
Sheri Robb was named a Walther Professor of Supportive Oncology at Indiana University School of Medicine. This is one of five endowed positions to develop a supportive oncology program that encompasses research and patient care.
Lucia Borriello was named assistant professor in the Department of Cancer and Cellular Biology at the Lewis Katz School of Medicine at Temple University.
Zachary J. Roberts was named executive vice president of research and development at Allogene Therapeutics Inc., a clinical-stage biotechnology company focused on the development of allogeneic CAR T products for cancer.
Ruben A. Mesa was named president and executive director of the cancer service line of Atrium Health.
Yolanda Sanchez was named director and CEO of The University of New Mexico Comprehensive Cancer Center.
U.S. Rep. Debbie Wasserman Schultz (D-FL), Sen. Amy Klobuchar (D-MN), Sen. Ben Cardin (D-MD), Rep. Brian Fitzpatrick (R-PA), and Rep. Mark DeSaulnier (CA-11) introduced The Comprehensive Cancer Survivorship Act, a legislation that will address gaps in survivorship care and develop standards to improve the overall patient-centered quality of care and navigation needs of cancer survivors and their families.
The Max Foundation, a global nonprofit organization that aims to accelerate health equity by delivering medication, technology, and supportive services to patients globally, will launch access to the Novartis therapy Scemblix (asciminib) in 36 low- and middle-income countries in 2023 for people living with chronic myeloid leukemia as part of the CancerPath to Care collaboration with Novartis.
The Prostate Cancer Foundation announced the four inaugural Class of 2022 TACTICAL (Therapy ACceleration To Intercept CAncer Lethality) Award recipients.
Barbara Burtness, professor of medicine (medical oncology), has been named chief translational research officer for Yale Cancer Center and Smilow Cancer Hospital, and associate cancer center director for translational research for Yale Cancer Center.
